Phenotypes associated with this allele
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
No mouse lines available in IMSR.
See publication links below for author information.
|
|
|
mortality/aging
|
• mice die by 3 months of age
|
neoplasm
|
• all mice develop leukemia by 1 to 2 weeks of months
|
|
Find Mice |
Using the International Mouse Strain Resource (IMSR)
No mouse lines available in IMSR.
See publication links below for author information.
|
|
|
mortality/aging
|
• mice die by 18 months of age
• 30% of mice die due to kidney failure from myeloid infiltrates in the kidney
• 70% of mice die from progression to blast crisis
• treatment with STI571 does not alter survival
|
neoplasm
|
• Sertoli cell tumors develop in 2% of mice
|
|
• 3% of mice develop hepatocarcinoma
|
|
• all mice develop chronic myeloid leukemia by 4 to 10 months of age with progression to blast crisis
• myeloid and lymphoid blasts appear in the peripheral blood, bone marrow, spleen, and liver
• leukemia can be induced in wild-type mice by engraftment of Sca+Lin- cells but not Sca-Lin+ cells
|
immune system
|
• spleens contain megakaryocyte as markers of myeloid metaplasia
|
|
• spleens contain megakaryocyte as markers of myeloid metaplasia
|
cellular
|
• centromere abnormalities are detected in 24% chronic phase cells and 62% of acute phase cells compared to 3% of wild-type cells
|
liver/biliary system
|
• livers contain megakaryocyte as markers of myeloid metaplasia
|
|
• 3% of mice develop hepatocarcinoma
|
renal/urinary system
|
• 30% of mice die due to kidney failure from myeloid infiltrates in the kidney
|
respiratory system
hematopoietic system
|
• spleens contain megakaryocyte as markers of myeloid metaplasia
|
|
• spleens contain megakaryocyte as markers of myeloid metaplasia
|
skeleton
growth/size/body
reproductive system
|
• Sertoli cell tumors develop in 2% of mice
|
endocrine/exocrine glands
|
• Sertoli cell tumors develop in 2% of mice
|